US biotech Trevi Therapeutics (Nasdaq: TRVI) has raised around $115 million in a public stock offering, giving it fresh ...

Food - Microbial contamination ? SalmonellaDistribution: British Columbia See the affected products and product photos for this recall Media and public enquiries SOURCE Canadian Food Inspection Agency ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

The nine activists from Ultima Generazione who, in May 2023, poured black liquid - made from vegetable charcoal - into the ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares and lifted the price target ...

Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...

First threats, then blows. In the heart of Rome: the shutters of two restaurants in the very center of the Capital, a few ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yester ...

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.

Trevi Therapeutics reported a smaller-than-expected loss per share for Q1 2025, with an EPS of -$0.09 compared to the forecasted -$0.13. According to InvestingPro data, two analysts have recently ...